Moderna has initiated Phase 1 clinical trials for its Bundibugyo Ebola vaccine in Canada, with the first participants vaccinated. The trial aims to assess the vaccine's safety and immune response as the Democratic Republic of Congo faces its second-largest Ebola outbreak in history. With over 3,800 cases reported, health officials express urgency in developing effective vaccines to combat the outbreak.